Kim Hutchings

Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis

Cynthia Yu‐Wai‐Man, Bradley Spencer‐Dene, Richard M. H. Lee et al. · Scientific Reports · 2017 · 66 citations · Full text

Life Sciences, Molecular Biology, Molecular Medicine +15

Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma

Kim Hutchings, Erika M. Lisabeth, Walajapet G. Rajeswaran et al. · Bioorganic & Medicinal Chemistry Letters · 2017 · 58 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +5

Discovery of Inhibitors of 4′-Phosphopantetheine Adenylyltransferase (PPAT) To Validate PPAT as a Target for Antibacterial Therapy

Boudewijn L. M. de Jonge, Grant K. Walkup, Sushmita D. Lahiri et al. · Antimicrobial Agents and Chemotherapy · 2013 · 44 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma

Dylan Kahl, Kim Hutchings, Erika M. Lisabeth et al. · Journal of Medicinal Chemistry · 2019 · 41 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +7

Synthesis and antibacterial activity of the C-7 side chain of 3-aminoquinazolinediones

Kim Hutchings, Tuan P. Tran, Edmund L. Ellsworth et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 23 citations

Pharmacy, Chemistry, Medicinal Chemistry +9